argenx NV ADR (ARGX)vsSinovac Biotech Ltd (SVA)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
SVA
Sinovac Biotech Ltd
$6.47
0.00%
HEALTHCARE · Cap: $642.44M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 730% more annual revenue ($4.24B vs $510.62M). ARGX leads profitability with a 30.5% profit margin vs 21.6%. SVA trades at a lower P/E of 6.7x. SVA earns a higher WallStSmart Score of 78/100 (B+).
ARGX
Buy63
out of 100
Grade: C+
SVA
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Margin of Safety
+85.8%
Fair Value
$45.44
Current Price
$6.47
$38.97 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 42.3%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 25 in profit
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
3.0% revenue growth
3.5% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : SVA
The strongest argument for SVA centers on P/E Ratio, Price/Book, Operating Margin. Profitability is solid with margins at 21.6% and operating margin at 42.3%.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : SVA
The primary concerns for SVA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while SVA is a value play — different risk/reward profiles.
SVA carries more volatility with a beta of 0.07 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
SVA scores higher overall (78/100 vs 63/100), backed by strong 21.6% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Sinovac Biotech Ltd
HEALTHCARE · BIOTECHNOLOGY · China
Sinovac Biotech Ltd., a biopharmaceutical company, focuses on the research, development, manufacture and marketing of vaccines against human infectious diseases in the People's Republic of China. The company is headquartered in Beijing, the People's Republic of China.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?